Epidemiology of Anaphylaxis: Contributions From the Last 10 Years

Tejedor-Alonso MA1,2, Moro-Moro M1, Múgica-García MV3

1Allergy Unit, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain 2Medicine and Surgery Department, Universidad Rey Juan Carlos, Alcorcón, Spain 3Allergy Service, Hospital Universitario de la Princesa, Madrid, Spain

J Investig Allergol Clin Immunol 2015; Vol. 25(3): 163-175

Abstract Knowledge of the epidemiology of anaphylaxis has improved during the last 10 years thanks to the increased number of publications with improved methodological robustness. Consequently, we better understand the distribution and frequency of anaphylaxis and the characteristics of fatal anaphylaxis.

Microbiome and Asthma: What Have Experimental Models Already Taught Us?

Journal of Immunology ResearchVolume 2015 (2015), Article ID 614758, 8 pageshttp://dx.doi.org/10.1155/2015/614758Review Article
R. Bonamichi-Santos, M. V. Aun, R. C. Agondi, J. Kalil, and P. Giavina-Bianchi

Abstract

Asthma is a chronic inflammatory disease that imposes a substantial burden on patients, their families, and the community. Although many aspects of the pathogenesis of classical allergic asthma are well known by the scientific community, other points are not yet understood.

Life Threatening Idiopathic Recurrent Angioedema Responding to Cannabis

Case Reports in ImmunologyVolume 2015 (2015), Article ID 780824, 3 pageshttp://dx.doi.org/10.1155/2015/780824Case Report
Amit Frenkel,1 Aviel Roy-Shapira,1 Brotfain Evgeni,1 Koyfman Leonid,1Abraham Borer,2 and Moti Klein1

Abstract

We present a case of a 27-year-old man with recurrent episodes of angioedema since he was 19, who responded well to treatment with medical grade cannabis. Initially, he responded to steroids and antihistamines, but several attempts to withdraw treatment resulted in recurrence.

Probiotics for prevention of atopic diseases in infants:systematic review and meta-analysis

1. 1. 
      
2. Gianvincenzo Zuccotti^1,8, 
3. Fabio Meneghin^2,8, 
4. Arianna Aceti^3,8,*, 
5. Giovanni Barone^4,8,
6. Maria Luisa Callegari^5,8, 
7. Antonio Di Mauro^6,8, 
8. Maria Pia Fantini^7,8, 
9. Davide Gori^7,8,
10. Flavia Indrio^6,8,9, 
11. Luca Maggio^4,8,9,
12. Lorenzo Morelli^5,8, 
13. Luigi Corvaglia^3,8,9,10and
14. The Italian Society of Neonatology.

15. 1. Allergy

       Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)
    2. Abstract

       Growing evidence underlines the pivotal role of infant gut colonization in the development of the immune system. The possibility to modify gut colonization through probiotic probiotic supplementation during pregnancy and early infancy in preventing atopic diseases.

Effect of anti-gliadin IgY antibody on epithelial intestinal integrity and inflammatory response induced by gliadin

Research article

Naiyana Gujral¹, Ju Won Suh^2* and Hoon H. Sunwoo^1*

BMC Immunology 2015, 16:41  doi:10.1186/s12865-015-0104-1

The electronic version of this article is the complete one and can be found online at:http://www.biomedcentral.com/1471-2172/16/41

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Abstract

Background

Pepsin-trypsin resistant gliadin (PT-gliadin) promotes intestinal tissue inflammation and increases paracellular permeability of immunogenic gliadin peptides into the lamina propria. This leads to the complications seen in the pathogenesis of celiac disease (CD). In this study, specific anti-gliadin IgY antibody was produced and evaluated for its efficacy on gliadin induced intestinal integrity impairment and proinflammatory effects on intestinal epithelial (Caco-2) cell culture model for CD.

Food allergy in irritable bowel syndrome: The case of non-celiac wheat sensitivity

• World J Gastroenterol
• v.21(23); 2015 Jun 21
• PMC4476871

World J Gastroenterol. 2015 Jun 21; 21(23): 7089–7109.

Published online 2015 Jun 21. doi:  10.3748/wjg.v21.i23.7089

PMCID: PMC4476871

Pasquale Mansueto, Alberto D’Alcamo, Aurelio Seidita, and Antonio Carroccio

Author information ► Article notes ► Copyright and License information ►

Abstract

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders, having a prevalence of 12%-30% in the general population. Most patients with IBS attribute their symptoms to adverse food reactions. We review the role of diet in the pathogenesis of IBS and the importance of dietary factors in the management of these patients.

Bilastine: new insight into antihistamine treatment

Review

Erminia Ridolo^1*, Marcello Montagni¹, Laura Bonzano¹, Cristoforo Incorvaia² and Giorgio Walter Canonica³

Clinical and Molecular Allergy 2015, 13:1  doi:10.1186/s12948-015-0008-x

Published: 15 April 2015

Abstract

Bilastine is a new second generation H1-antihistamine recently approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU). Bilastine epitomizes the evolution of research on antihistamines concerning both efficacy and safety.

Clinical development methodology for infusion-related reactions with monoclonal antibodies

Review
Published online 17 July 2015
OPEN

Citation: Clinical & Translational Immunology (2015) 4, e39; doi:10.1038/cti.2015.14

Lucette Doessegger¹ and Maria Longauer Banholzer¹

¹Safety Risk Management, Licensing and Early Development (LEAD), F. Hoffmann-La Roche AG, Basel, Switzerland

Correspondence: Dr L Doessegger, Safety Risk Management, F. Hoffmann-La Roche, Grenzacherstrasse 124, Basel 4070, Switzerland. E-mail: lucette.doessegger@roche.com

Received 20 March 2015; Revised 2 June 2015; Accepted 2 June 2015

of page

Abstract

Infusion-related reactions (IRRs) are common with monoclonal antibodies (mAbs) and timely related to drug administration and have been reported as anaphylaxis, anaphylactoid reactions and cytokine release syndrome, among other terms used. We address risk management measures for individual patients and for the study and propose a consistent reporting approach in an attempt to allow cross-molecule comparisons. Once the symptoms of IRR have resolved, the mAb may be restarted.